Aadi Bioscience, Inc. (NASDAQ:AADI) Short Interest Down 13.7% in January

Aadi Bioscience, Inc. (NASDAQ:AADI) was the target of a significant drop in short interest during the month of January. As of January 15th, there was short interest totalling 472,700 shares, a drop of 13.7% from the December 31st total of 547,500 shares. Approximately 2.3% of the company’s shares are short sold. Based on an average trading volume of 349,100 shares, the short-interest ratio is currently 1.4 days.

Aadi Bioscience Stock Performance

NASDAQ AADI opened at $2.88 on Monday. The firm has a 50 day simple moving average of $2.84 and a 200-day simple moving average of $2.18. Aadi Bioscience has a one year low of $1.21 and a one year high of $3.81. The firm has a market cap of $70.99 million, a price-to-earnings ratio of -1.26 and a beta of 0.65.

Aadi Bioscience (NASDAQ:AADI) last issued its earnings results on Wednesday, November 6th. The company reported ($0.46) EPS for the quarter, hitting analysts’ consensus estimates of ($0.46). Aadi Bioscience had a negative net margin of 246.06% and a negative return on equity of 71.87%. The firm had revenue of $7.21 million during the quarter, compared to the consensus estimate of $6.55 million. During the same quarter in the previous year, the firm posted ($0.60) earnings per share. Equities analysts predict that Aadi Bioscience will post -2.04 EPS for the current fiscal year.

Institutional Trading of Aadi Bioscience

A number of hedge funds and other institutional investors have recently bought and sold shares of AADI. BML Capital Management LLC acquired a new position in shares of Aadi Bioscience during the 3rd quarter worth approximately $4,120,000. Peapod Lane Capital LLC acquired a new position in Aadi Bioscience in the 4th quarter valued at $1,397,000. Point72 Asia Singapore Pte. Ltd. acquired a new position in Aadi Bioscience in the 2nd quarter valued at $37,000. Finally, XTX Topco Ltd acquired a new position in Aadi Bioscience in the 3rd quarter valued at $32,000. 52.08% of the stock is currently owned by institutional investors and hedge funds.

Aadi Bioscience Company Profile

Aadi Bioscience, Inc, a biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug product candidate comprises FYARRO, a form of sirolimus protein-bound particles for injectable suspension for the treatment in adult patients with advanced unresectable or metastatic malignant PEComa.